Effect of Autologous Cord Blood Infusion on Motor Function and Brain Connectivity in Young Children with Cerebral Palsy: A Randomized, Placebo-Controlled Trial

Jessica M Sun, Allen W Song, Laura E Case, Mohamad A Mikati, Kathryn E Gustafson, Ryan Simmons, Ricki Goldstein, Jodi Petry, Colleen McLaughlin, Barbara Waters-Pick, Lyon W Chen, Stephen Wease, Beth Blackwell, Gordon Worley, Jesse Troy, Joanne Kurtzberg, Jessica M Sun, Allen W Song, Laura E Case, Mohamad A Mikati, Kathryn E Gustafson, Ryan Simmons, Ricki Goldstein, Jodi Petry, Colleen McLaughlin, Barbara Waters-Pick, Lyon W Chen, Stephen Wease, Beth Blackwell, Gordon Worley, Jesse Troy, Joanne Kurtzberg

Abstract

Cerebral palsy (CP) is a condition affecting young children that causes lifelong disabilities. Umbilical cord blood cells improve motor function in experimental systems via paracrine signaling. After demonstrating safety, we conducted a phase II trial of autologous cord blood (ACB) infusion in children with CP to test whether ACB could improve function (ClinicalTrials.gov, NCT01147653; IND 14360). In this double-blind, placebo-controlled, crossover study of a single intravenous infusion of 1-5 × 107 total nucleated cells per kilogram of ACB, children ages 1 to 6 years with CP were randomly assigned to receive ACB or placebo at baseline, followed by the alternate infusion 1 year later. Motor function and magnetic resonance imaging brain connectivity studies were performed at baseline, 1, and 2 years post-treatment. The primary endpoint was change in motor function 1 year after baseline infusion. Additional analyses were performed at 2 years. Sixty-three children (median age 2.1 years) were randomized to treatment (n = 32) or placebo (n = 31) at baseline. Although there was no difference in mean change in Gross Motor Function Measure-66 (GMFM-66) scores at 1 year between placebo and treated groups, a dosing effect was identified. In an analysis 1 year post-ACB treatment, those who received doses ≥2 × 107 /kg demonstrated significantly greater increases in GMFM-66 scores above those predicted by age and severity, as well as in Peabody Developmental Motor Scales-2 Gross Motor Quotient scores and normalized brain connectivity. Results of this study suggest that appropriately dosed ACB infusion improves brain connectivity and gross motor function in young children with CP. Stem Cells Translational Medicine 2017;6:2071-2078.

Keywords: Autologous stem cell transplantation; Cellular therapy; Clinical Trials; Cord blood; Human cord blood; Nervous system; Umbilical cord blood.

© 2017 The Authors Stem Cells Translational Medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.

Figures

Figure 1
Figure 1
Study schema and distribution of subjects in analysis cohorts. (A): Gross motor evaluations (GMFM‐66, Peabody Developmental Motor Scales‐2 [PDMS‐2]) and brain MRI were performed at each visit. (B): Diagram of subjects evaluable via change in observed‐expected GMFM‐66 score (pink), PDMS‐2 score (green), and MRI (yellow) from baseline to 1 year. (C): Diagram of subjects evaluable via change in observed‐expected GMFM‐66 score, PDMS‐2 gross motor quotient score, and MRI 1 year after cord blood treatment (given at either baseline or 1 year). Abbreviations: GMFM‐66, Gross Motor Function Measure‐66; MRI, magnetic resonance imaging.
Figure 2
Figure 2
GMFM‐66 scores from baseline to year 1 by randomized treatment assignment and cell dose. (A): Distribution of GMFM‐66 score at baseline and 1 year in patients randomized to placebo and autologous cord blood. Lines connect the group means (circles) over time. (B): GMFM‐66 change scores based on median cell doses (Precryopreservation doses: Low, <3 × 107/kg, N = 16 vs. High, ≥3 × 107/kg, N = 16; Infused doses: Low, <1.98 × 107/kg, N = 16 vs. High: ≥1.98 × 107/kg, N = 16). (C): One year Observed‐Expected GMFM‐66 scores in patients ≥2 years of age at baseline based on infused cell dose (Low, N = 10; High, N = 9; Placebo, N = 19). (D): PDMS‐2 gross motor quotient change scores based on infused cell dose (Low, N = 13; High, N = 11; Placebo, N = 25). Abbreviation: GMFM‐66, Gross Motor Function Measure‐66.
Figure 3
Figure 3
Gross motor function and brain connectivity 1 year after autologous cord blood treatment by cell dose. High dose ≥2 × 107/kg, low dose <2 × 107/kg. (A): Observed‐Expected GMFM‐66 scores 1 year after treatment in patients ≥2 years of age at the time of ACB infusion. (B): Peabody Developmental Motor Scales‐2 gross motor change scores 1 year after treatment. (C): Change in normalized whole brain connectivity 1 year after treatment. (D): Connectome representation. The nodes and edges included are those that demonstrated significantly increased improvement in children receiving high doses compared with those receiving low doses, as indicated by the color chart, with insignificant nodes shown in gray. Representative nodes in the sensorimotor network with significant changes correlated with improvement in GMFM‐66 scores include the pre‐ and post‐central gyri, basal ganglia, and brain stem. Abbreviation: GMFM‐66, Gross Motor Function Measure‐66.

References

    1. Arneson CL, Durkin MS, Benedict RE et al. Prevalence of cerebral palsy: Autism and Developmental Disabilities Monitoring Network, three sites, United States, 2004. Disabil Health J 2009;2:45–48.
    1. Drobyshevsky A, Cotten CM, Shi Z et al. Human umbilical cord blood cells ameliorate motor deficits in rabbits in a cerebral palsy model. Dev Neurosci 2015;37:349–362.
    1. Meier C, Middelanis J, Wasielewski B et al. Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells. Pediatr Res 2006;59:244–249.
    1. Sun J, Allison J, McLaughlin C et al. Differences in quality between privately and publicly banked umbilical cord blood units: A pilot study of autologous cord blood infusion in children with acquired neurologic disorders. Transfusion 2010; 50:1980–1987.
    1. Rubinstein P, Dobrila L, Rosenfield RE et al. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci USA 1995;92:10119–10122.
    1. Folio MR. PDMS‐2: Peabody Developmental Motor Scales. 2nd ed Austin: Pro‐Ed, 2000.
    1. Russell DJ. Gross motor function measure (GMFM‐66 & GMFM‐88) user's manual. London: Mac Keith, 2002.
    1. Mori S, Crain BJ, Chacko VP et al. Three‐dimensional tracking of axonal projections in the brain by magnetic resonance imaging. Ann Neurol 1999;45:265–269.
    1. Mori S, Zhang J. Principles of diffusion tensor imaging and its applications to basic neuroscience research. Neuron 2006;51:527–539.
    1. Oishi K, Faria A, Jiang H et al. Atlas‐based whole brain white matter analysis using large deformation diffeomorphic metric mapping: Application to normal elderly and Alzheimer's disease participants. Neuroimage 2009;46:486–499.
    1. Faria AV, Hoon A, Stashinko E et al. Quantitative analysis of brain pathology based on MRI and brain atlases–applications for cerebral palsy. Neuroimage 2011;54:1854–1861.
    1. Avants BB, Tustison NJ, Song G et al. A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage 2011;54:2033–2044.
    1. Oeffinger D, Bagley A, Rogers S et al. Outcome tools used for ambulatory children with cerebral palsy: Responsiveness and minimum clinically important differences. Dev Med Child Neurol 2008;50:918–925.
    1. Rosenbaum PL, Walter SD, Hanna SE et al. Prognosis for gross motor function in cerebral palsy: Creation of motor development curves. JAMA 2002; 288:1357–1363.
    1. Russell DJ, Avery LM, Rosenbaum PL et al. Improved scaling of the gross motor function measure for children with cerebral palsy: Evidence of reliability and validity. Phys Ther 2000;80:873–885.
    1. Hanna SE, Bartlett DJ, Rivard LM et al. Reference curves for the Gross Motor Function Measure: Percentiles for clinical description and tracking over time among children with cerebral palsy. Phys Ther 2008;88:596–607.
    1. Englander ZA, Sun J, Laura C et al. Brain structural connectivity increases concurrent with functional improvement: Evidence from diffusion tensor MRI in children with cerebral palsy during therapy. Neuroimage Clin 2015;7:315–324.
    1. Rubinstein P, Stevens CE. Placental blood for bone marrow replacement: The New York Blood Center's program and clinical results. Baillieres Best Pract Res Clin Haematol 2000;13:565–584.
    1. Min K, Song J, Kang JY et al. Umbilical cord blood therapy potentiated with erythropoietin for children with cerebral palsy: A double‐blind, randomized, placebo‐controlled trial. Stem Cells 2013;31:581–591.
    1. Kang M, Min K, Jang J et al. Involvement of immune responses in the efficacy of cord blood cell therapy for cerebral palsy. Stem Cells Dev 2015;24:2259–2268.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever